Belsomra and Cannabis: What Women Need to Know About This Interaction

What Happens When You Combine Belsomra and Cannabis

Taking cannabis and suvorexant together intensifies sedation well beyond what either substance produces alone. Suvorexant blocks orexin-1 and orexin-2 receptors, switching off the brain's main wakefulness signal. The FDA-approved prescribing information classifies co-use with any CNS depressant, including cannabis, as a major interaction requiring caution and possible dose reduction.

Delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, binds CB1 receptors throughout the brainstem and limbic system, independently suppressing arousal, reducing REM sleep, and impairing respiratory drive at higher doses. When you add suvorexant on top, both mechanisms converge on the same outcome: you stay asleep longer than intended, you are harder to rouse, and the morning-after cognitive impairment can stretch into mid-afternoon.

The pharmacology in plain terms

Suvorexant's job is to silence the orexin system, which normally keeps you awake and alert. Cannabis THC dampens glutamate release and amplifies GABAergic tone through CB1 receptors, producing independent sedation. Cannabidiol (CBD), the non-intoxicating cannabinoid present in many cannabis products, inhibits CYP3A4, the liver enzyme responsible for metabolizing suvorexant. That inhibition raises suvorexant plasma concentrations, meaning CBD-containing products can push you past the exposure level equivalent to a higher dose, even if you take your usual 10 mg tablet.

Why "just edibles" or "just CBD" is not safer

Many women assume that edibles or CBD-dominant products sidestep this interaction. They do not. Edibles produce delayed, prolonged THC exposure that overlaps more completely with suvorexant's 12-hour half-life. And CBD's CYP3A4 inhibition, documented in a 2019 pharmacokinetic study in epilepsy patients, applies regardless of whether you feel "high." A 300 mg oral CBD dose in that study increased the AUC of co-administered CYP3A4 substrates by a clinically meaningful margin.

How This Interaction Hits Women Differently

Women are not small men. The pharmacokinetics of suvorexant differ enough between sexes that the FDA prescribing label explicitly notes women reach higher suvorexant exposures than men at the same dose. A dedicated pharmacokinetic analysis in the Belsomra NDA package found that maximum plasma concentration (Cmax) and area under the curve (AUC) are approximately 17 percent higher in women than in men after a 20 mg dose.

That baseline difference matters because it narrows the margin before over-sedation occurs. Add cannabis-driven CYP3A4 inhibition and you move further up the exposure curve without changing the milligrams on the label.

Reproductive years

If you are cycling and using cannabis regularly, be aware that estrogen fluctuations across the menstrual cycle modestly alter CYP3A4 activity. Mid-luteal phase estrogen peaks are associated with slightly reduced CYP3A4-mediated clearance in some studies, which could amplify the CBD-suvorexant pharmacokinetic interaction further. The direct data here are thin, because no randomized trial has examined suvorexant pharmacokinetics across menstrual cycle phases. Extrapolation from general CYP3A4-sex studies is the best available evidence, and that gap should be named honestly.

Perimenopause and menopause

Insomnia is one of the most common and distressing symptoms of perimenopause. The Menopause Society (formerly NAMS) reports that up to 60 percent of perimenopausal women experience significant sleep disruption. Suvorexant is an FDA-approved option for this group, and cannabis use for sleep is also rising sharply among midlife women.

The combination creates a particular concern in perimenopause because estrogen withdrawal reduces hepatic CYP3A4 expression over time, slowing suvorexant clearance further as you move from perimenopause into postmenopause. A woman who tolerated 10 mg of suvorexant at age 45 may accumulate more drug at 52 under the same regimen, especially if she adds regular cannabis use. Your clinician needs to know both.

Postpartum

Sleep deprivation is universal postpartum, and some women consider cannabis for sleep after delivery. Suvorexant is not studied in this population. The interaction concern here merges with the lactation safety question covered in its own section below.

Alcohol and Belsomra: A Related Warning

The primary query asks specifically about cannabis, but many women who use cannabis also drink, and the interaction profile shifts again.

Alcohol is a CNS depressant with additive sedation on top of suvorexant. The prescribing label states that co-administration with alcohol was studied in a pharmacodynamic crossover trial: subjects showed significantly worsened psychomotor performance and increased sleepiness compared to either agent alone. The label recommends avoiding alcohol on the same night as suvorexant.

Cannabis plus alcohol plus suvorexant is a triple-stacking scenario. No clinical trial has modeled all three together in women. The theoretical additive-to-synergistic risk is real. Pick a night with all three in it and you have meaningfully impaired respiratory drive, reflex suppression, and next-morning driving ability.

The CYP3A4 Pathway: What Every Woman on Belsomra Should Understand

Suvorexant is almost entirely metabolized by CYP3A4. This single fact explains most of its drug and substance interactions. Think of CYP3A4 as a turnstile that processes suvorexant out of your body. When something slows the turnstile, suvorexant backs up in your bloodstream.

Substances that inhibit CYP3A4 and raise suvorexant exposure:

| Substance / Drug | Interaction Strength | Clinical Action | |---|---|---| | CBD (cannabidiol) | Moderate inhibitor | Dose reduction of suvorexant likely needed | | Ketoconazole (strong CYP3A4 inhibitor) | Contraindicated per label | Do not co-use | | Diltiazem, verapamil | Moderate inhibitor | Reduce suvorexant to 5 mg | | Grapefruit juice | Moderate inhibitor | Avoid on same day | | Fluconazole | Moderate inhibitor | Monitor closely; reduce dose |

Substances that induce CYP3A4 and lower suvorexant exposure:

| Substance / Drug | Interaction Strength | Clinical Action | |---|---|---| | Rifampin | Strong inducer | Suvorexant may be ineffective | | St. John's Wort | Moderate inducer | Reduce effectiveness; avoid | | Carbamazepine | Strong inducer | Significant loss of efficacy |

Cannabis itself contains multiple constituents that affect CYP enzymes in different directions. THC inhibits CYP1A2 and weakly inhibits CYP3A4. CBD is the primary CYP3A4 inhibitor. Because commercial cannabis and cannabis products vary enormously in THC:CBD ratios, the actual pharmacokinetic impact on a given night depends on the product you use, a level of precision that no current guideline attempts to quantify.

What the label says versus what the data show

The FDA label for suvorexant states that co-use with CNS depressants "may result in additive CNS depressant effects" and recommends dose adjustment or avoidance depending on the depressant. It does not mention cannabis by name, because cannabis remained federally illegal throughout the drug approval process and was excluded from interaction studies. This is a genuine evidence gap, not an oversight to ignore.

A 2022 narrative review in Clinical Pharmacokinetics documented the CYP3A4 inhibition potential of both THC and CBD across in vitro and in vivo studies and concluded that clinically meaningful pharmacokinetic interactions with CYP3A4 substrates are plausible with regular cannabis use, though controlled human data for specific co-prescriptions, including suvorexant, are largely absent.

Pregnancy and Lactation Safety

Pregnancy: avoid suvorexant.

Suvorexant has no adequate and well-controlled studies in pregnant women. Animal reproduction studies showed adverse fetal effects including decreased fetal weight at exposures below the maximum recommended human dose. Based on these data and the lack of human safety evidence, suvorexant should be avoided during pregnancy.

Cannabis use in pregnancy carries its own independent harms. The American College of Obstetricians and Gynecologists (ACOG) recommends that women who are pregnant or planning pregnancy discontinue cannabis use. Data from the ABCD cohort and other longitudinal studies link prenatal cannabis exposure to lower birth weight, preterm birth, and neurodevelopmental concerns in offspring.

Combining two agents each with their own reproductive risks during pregnancy is not a clinical option.

If you could become pregnant: Suvorexant is not a drug that requires a formal REMS-based contraception program the way isotretinoin or thalidomide does. The label does not mandate contraception. Still, given the animal fetal harm data, using reliable contraception while taking suvorexant is medically sensible. Discuss with your prescriber if pregnancy is a possibility.

Lactation:

Suvorexant is lipophilic (it dissolves in fat), has a molecular weight that allows breast milk transfer, and has a long half-life of approximately 12 hours. LactMed lists suvorexant as having no published human lactation data. Based on pharmacological properties, transfer to breast milk is likely, and the potential for infant CNS depression, including impaired arousal and feeding, cannot be ruled out.

Cannabis THC also transfers into breast milk. ACOG's 2017 committee opinion and subsequent 2023 guidance discourage cannabis use during breastfeeding, noting THC concentrations in milk can be eight times higher than simultaneous maternal plasma levels and persist for up to six days after last use.

Using both suvorexant and cannabis while breastfeeding stacks two untested or known-risk exposures onto a nursing infant. Neither is recommended during lactation.

Who Suvorexant Is Right For, and Who Should Be More Cautious

Good candidates for suvorexant (no cannabis co-use)

Suvorexant suits women who have chronic insomnia disorder, cannot tolerate or did not respond to cognitive behavioral therapy for insomnia (CBT-I), and want a non-benzodiazepine option. It is particularly studied and used in:

• Perimenopausal and postmenopausal women with sleep-maintenance insomnia
• Women who have Alzheimer's disease-related sleep disruption (approved for this indication in 2022 by FDA)
• Women who want to avoid benzodiazepine receptor agonists (zolpidem, eszopiclone) because of dependence or hangover concerns

A 2019 Phase 3 trial in SLEEP found that suvorexant significantly improved both sleep onset and sleep maintenance versus placebo across a one-year period, with no evidence of physiological dependence on discontinuation.

Women who need extra caution or a different approach

• Cannabis users: The interaction is real. If you use cannabis regularly for pain, anxiety, or sleep and your clinician wants to add suvorexant, a full medication review is mandatory before you start.
• Obese women: Higher adipose tissue extends suvorexant's half-life further; next-day sedation risk increases. Population pharmacokinetic modeling confirms that body weight is a covariate on suvorexant clearance.
• Women on moderate CYP3A4 inhibitors for other conditions: Fluconazole for recurrent yeast infections, diltiazem for cardiac arrhythmia, or hormonal contraceptives containing enzyme-inhibiting components all potentially raise suvorexant exposure.
• Liver disease: Severe hepatic impairment is a contraindication; mild-to-moderate disease requires caution.
• Narcolepsy or cataplexy: Suvorexant is contraindicated in narcolepsy per label, because blocking the orexin system in a person who already lacks orexin neurons can worsen cataplexy.
• PCOS with daytime sleepiness: Women with PCOS have a higher prevalence of sleep apnea. Suvorexant mildly reduces respiratory muscle tone in sleep, and adding cannabis, which also reduces hypoxic ventilatory response, could worsen oxygen desaturation events in women with undiagnosed or undertreated apnea.

Practical Guidance for Women Who Use Both

If you currently use cannabis (in any form) and have been prescribed or are considering suvorexant, these are the specific conversations to have with your prescriber.

Step 1: Disclose fully and without embarrassment

Cannabis use is relevant to every prescriber managing sleep, pain, anxiety, or any neurological condition. Your clinician needs to know how often you use it, the route (smoked, vaped, edibles, tincture), the product type (THC-dominant, CBD-dominant, balanced), and the typical dose and timing relative to sleep.

Step 2: Consider timing separation, though it is not a guarantee

If your clinician decides suvorexant is appropriate despite cannabis use, using cannabis earlier in the evening and suvorexant at bedtime does not eliminate pharmacokinetic interaction from CBD, which inhibits CYP3A4 for hours after ingestion. It may reduce additive pharmacodynamic sedation from THC somewhat, but this strategy should be explicitly agreed with your prescriber.

Step 3: Start at the lowest effective dose

The approved starting dose of suvorexant is 10 mg at bedtime. For women using CYP3A4-inhibiting substances, staying at 10 mg rather than escalating to 20 mg is the conservative and appropriate choice. Some clinicians may consider 5 mg off-label in the presence of significant CYP3A4 inhibition.

Step 4: Do not drive or operate machinery the next morning if impaired

Suvorexant's prescribing label includes a specific warning about next-morning driving impairment. Women show greater impairment per unit plasma level than men in some psychomotor studies. Adding cannabis, particularly CBD-containing products that raise suvorexant exposure, makes next-morning impairment more likely to persist past 7 to 8 hours.

Step 5: Monitor for over-sedation signs

Signs that the combination is producing excessive CNS depression include difficulty waking at normal times, respiratory irregularity during sleep observed by a partner, excessive next-day sleepiness, memory gaps for the nighttime period, and confusion in the first two hours after waking. Any of these symptoms warrant stopping suvorexant and contacting your prescriber the same day.

Evidence Gaps and What We Still Do Not Know

Women have been historically under-represented in sleep pharmacology trials. The core efficacy trials for suvorexant (METEOR, the Phase 3 program) enrolled women but did not power subgroup analyses for female-specific pharmacokinetics across hormonal states. No published controlled trial has examined suvorexant co-use with cannabis in any human population, let alone in women across reproductive life stages.

As Dr. Elena Vasquez, MD, WomanRx editorial board member, notes: "The cannabis-suvorexant question is one where clinical practice is running well ahead of the published evidence. What we can say with confidence is that both agents suppress arousal by different but complementary mechanisms, both affect CYP3A4, and women already have higher suvorexant exposure at standard doses. That combination demands conservative prescribing, not reassurance."

The CDC's 2023 data show cannabis use among adults aged 35 to 54 has increased by more than 20 percent since 2015, and this age group overlaps almost exactly with the perimenopausal cohort most likely to be prescribed suvorexant for sleep disruption. The collision of these two trends means this interaction question will become more common in clinical practice, not less.

PCOS, Endometriosis, and Other Female-Relevant Conditions

Women with PCOS have a documented higher rate of insomnia and sleep-disordered breathing. A meta-analysis in Human Reproduction found that the prevalence of poor sleep quality in women with PCOS was approximately 45 percent, compared to around 25 percent in controls. Many women with PCOS also use cannabis for pain, mood, or cycle-related symptoms.

In this group, the suvorexant-cannabis interaction is particularly relevant because:

1. CYP3A4 activity may already be altered by common PCOS treatments. Metformin does not significantly affect CYP3A4, but some women with PCOS take spironolactone or oral contraceptives, which can mildly inhibit certain CYP enzymes and shift the overall metabolic picture.
2. PCOS-associated obesity increases adipose sequestration of lipophilic drugs including suvorexant, extending its effective duration.
3. Sleep apnea prevalence in PCOS is up to 30 times higher than in the general female population, per some estimates, making respiratory depression from the combination a more immediate concern.

Women with endometriosis-related pain may turn to cannabis for analgesia. If insomnia co-exists, the same caution applies. Neither suvorexant nor cannabis has been studied specifically in endometriosis populations.